146 related articles for article (PubMed ID: 31425479)
1. Absolute lymphocyte count as a prognostic biomarker for overall survival in patients with advanced melanoma treated with ipilimumab.
Postow MA; Chasalow SD; Kuk D; Panageas KS; Cheng ML; Yuan J; Wolchok JD
Melanoma Res; 2020 Feb; 30(1):71-75. PubMed ID: 31425479
[TBL] [Abstract][Full Text] [Related]
2. Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab.
Balatoni T; Ladányi A; Fröhlich G; Czirbesz K; Kovács P; Pánczél G; Bence E; Plótár V; Liszkay G
Pathol Oncol Res; 2020 Jan; 26(1):317-325. PubMed ID: 30225783
[TBL] [Abstract][Full Text] [Related]
3. Investigation of clinical factors associated with longer overall survival in advanced melanoma patients treated with sequential ipilimumab.
Muto Y; Kitano S; Tsutsumida A; Namikawa K; Takahashi A; Nakamura Y; Yamanaka T; Yamamoto N; Yamazaki N
J Dermatol; 2019 Jun; 46(6):498-506. PubMed ID: 30945333
[TBL] [Abstract][Full Text] [Related]
4. Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab.
Martens A; Wistuba-Hamprecht K; Yuan J; Postow MA; Wong P; Capone M; Madonna G; Khammari A; Schilling B; Sucker A; Schadendorf D; Martus P; Dreno B; Ascierto PA; Wolchok JD; Pawelec G; Garbe C; Weide B
Clin Cancer Res; 2016 Oct; 22(19):4848-4858. PubMed ID: 27169993
[TBL] [Abstract][Full Text] [Related]
5. Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab.
Martens A; Wistuba-Hamprecht K; Geukes Foppen M; Yuan J; Postow MA; Wong P; Romano E; Khammari A; Dreno B; Capone M; Ascierto PA; Di Giacomo AM; Maio M; Schilling B; Sucker A; Schadendorf D; Hassel JC; Eigentler TK; Martus P; Wolchok JD; Blank C; Pawelec G; Garbe C; Weide B
Clin Cancer Res; 2016 Jun; 22(12):2908-18. PubMed ID: 26787752
[TBL] [Abstract][Full Text] [Related]
6. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival.
Ku GY; Yuan J; Page DB; Schroeder SE; Panageas KS; Carvajal RD; Chapman PB; Schwartz GK; Allison JP; Wolchok JD
Cancer; 2010 Apr; 116(7):1767-75. PubMed ID: 20143434
[TBL] [Abstract][Full Text] [Related]
7. High cytotoxic T-lymphocyte-associated antigen 4 and phospho-Akt expression in tumor samples predicts poor clinical outcomes in ipilimumab-treated melanoma patients.
Chakravarti N; Ivan D; Trinh VA; Glitza IC; Curry JL; Torres-Cabala C; Tetzlaff MT; Bassett RL; Prieto VG; Hwu WJ
Melanoma Res; 2017 Feb; 27(1):24-31. PubMed ID: 27768639
[TBL] [Abstract][Full Text] [Related]
8. Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis.
Alrabadi NN; Abushukair HM; Ababneh OE; Syaj SS; Al-Horani SS; Qarqash AA; Darabseh OA; Al-Sous MM; Al-Aomar SR; Ahmed YB; Haddad R; Al Qarqaz FA
Clin Transl Oncol; 2021 Sep; 23(9):1885-1904. PubMed ID: 33877531
[TBL] [Abstract][Full Text] [Related]
9. Exploratory analysis of clinical benefit of ipilimumab and nivolumab treatment in patients with metastatic melanoma from a single institution.
Vila CM; Moreno FA; Estébanez MM; Ares GR; Villacampa G; Dashti P; Oberoi HS; Martin-Huertas R; Jares P; Alos L; Teixido C; Rull R; Sanchez M; Malvehy J; Carcelero E; Valduvieco I; Fernandez AA
Clin Transl Oncol; 2022 Feb; 24(2):319-330. PubMed ID: 34420138
[TBL] [Abstract][Full Text] [Related]
10. Personalised medicine: Development and external validation of a prognostic model for metastatic melanoma patients treated with ipilimumab.
Valpione S; Martinoli C; Fava P; Mocellin S; Campana LG; Quaglino P; Ferrucci PF; Pigozzo J; Astrua C; Testori A; Chiarion-Sileni V
Eur J Cancer; 2015 Sep; 51(14):2086-94. PubMed ID: 26227432
[TBL] [Abstract][Full Text] [Related]
11. Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma.
Jang SR; Nikita N; Banks J; Keith SW; Johnson JM; Wilson M; Lu-Yao G
JAMA Netw Open; 2021 Dec; 4(12):e2136823. PubMed ID: 34854905
[TBL] [Abstract][Full Text] [Related]
12. Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition.
Laino AS; Woods D; Vassallo M; Qian X; Tang H; Wind-Rotolo M; Weber J
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581042
[TBL] [Abstract][Full Text] [Related]
13. Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma.
Rosner S; Kwong E; Shoushtari AN; Friedman CF; Betof AS; Brady MS; Coit DG; Callahan MK; Wolchok JD; Chapman PB; Panageas KS; Postow MA
Cancer Med; 2018 Mar; 7(3):690-697. PubMed ID: 29468834
[TBL] [Abstract][Full Text] [Related]
14. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.
Hodi FS; Chiarion-Sileni V; Gonzalez R; Grob JJ; Rutkowski P; Cowey CL; Lao CD; Schadendorf D; Wagstaff J; Dummer R; Ferrucci PF; Smylie M; Hill A; Hogg D; Marquez-Rodas I; Jiang J; Rizzo J; Larkin J; Wolchok JD
Lancet Oncol; 2018 Nov; 19(11):1480-1492. PubMed ID: 30361170
[TBL] [Abstract][Full Text] [Related]
15. Cohort versus patient level simulation for the economic evaluation of single versus combination immuno-oncology therapies in metastatic melanoma.
Gibson EJ; Begum N; Koblbauer I; Dranitsaris G; Liew D; McEwan P; Yuan Y; Juarez-Garcia A; Tyas D; Pritchard C
J Med Econ; 2019 Jun; 22(6):531-544. PubMed ID: 30638416
[No Abstract] [Full Text] [Related]
16. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma.
Weber JS; Kudchadkar RR; Yu B; Gallenstein D; Horak CE; Inzunza HD; Zhao X; Martinez AJ; Wang W; Gibney G; Kroeger J; Eysmans C; Sarnaik AA; Chen YA
J Clin Oncol; 2013 Dec; 31(34):4311-8. PubMed ID: 24145345
[TBL] [Abstract][Full Text] [Related]
17. Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response.
Stein JE; Soni A; Danilova L; Cottrell TR; Gajewski TF; Hodi FS; Bhatia S; Urba WJ; Sharfman WH; Wind-Rotolo M; Edwards R; Lipson EJ; Taube JM
Ann Oncol; 2019 Apr; 30(4):589-596. PubMed ID: 30689736
[TBL] [Abstract][Full Text] [Related]
18. The full blood count as a biomarker of outcome and toxicity in ipilimumab-treated cutaneous metastatic melanoma.
Khoja L; Atenafu EG; Templeton A; Qye Y; Chappell MA; Saibil S; Hogg D; Butler MO; Joshua AM
Cancer Med; 2016 Oct; 5(10):2792-2799. PubMed ID: 27683208
[TBL] [Abstract][Full Text] [Related]
19. Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies.
Lebbé C; Weber JS; Maio M; Neyns B; Harmankaya K; Hamid O; O'Day SJ; Konto C; Cykowski L; McHenry MB; Wolchok JD
Ann Oncol; 2014 Nov; 25(11):2277-2284. PubMed ID: 25210016
[TBL] [Abstract][Full Text] [Related]
20. Trough levels of ipilimumab in serum as a potential biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab.
Koguchi Y; Iwamoto N; Shimada T; Chang SC; Cha J; Curti BD; Urba WJ; Piening BD; Redmond WL
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34620702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]